Investigating the effect of the digital Patient Benefit Assessment Scale, a goals-based tool, on patient-centred outcomes in the healthcare process.

Investigating the effect of the digital Patient Benefit Assessment Scale, a goals-based tool, on patient-centred outcomes in the healthcare process. - The effect of the P-BAS on patient outcomes in the healthcare process.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON56868

Enrollment

225

Registered

2024-01-20

Start date

2024-06-26

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittent claudication

Interventions

Before patients have their first outpatient consult, patients randomised into a control group and an intervention group. Both groups are asked to fill in questionnaires regarding their quality of li

Eligibility

Age

65 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age >= 65 years • Patients who can read, speak and understand the Dutch language • Patients with an outpatient consult whereby the consultation is expected to contain a decision with regard to treatment options • Capable to fill in digital questionnaires and having access to the Internet and DigiD

Exclusion criteria

Exclusion criteria: - Cognitive limitations (e.g. delirium or dementia), as assessed by the health care provider - Patients without an email account

Design outcomes

Primary

Measure	Time frame
To measure the effect of the digital picture based Patient Benefit Assessment Scale on patient-centred outcomes regarding their health care process, the first eight domains of the factor health care process of the PPPC-R questionnaire (appendix 2) are asked after the outpatient consult, and at three and six months.	—

Secondary

Measure	Time frame
• To assess whether the use of the digital picture based Patient Benefit Assessment Scale improves the level of shared decision making. The I-Share questionnaire (appendix 3) is asked after the outpatient consult. • To assess whether the use of the digital picture baseds Patient Benefit Assessment Scale improves the quality of life of patients, measured with the SF-36 (appendix 4) at baseline and after three and six months after the first outpatient consult. level of shared decision making during the consultation experienced by patients. • To study the cost effectiveness of the digital picture based Patient Benefit Assessment Scale, measured with the EQ-5D-5L (appendix 5) at baseline and after three and six months after the first outpatient consult. • To examine whether the chosen treatment options of the intervention group differ from those of the control group. Based on the (electronic patient record the chosen treatment options can be analysed. The final comparison between treatments of the intervention group and the treatments of the control group is made after six months. ).	—

Measure

Time frame

• To assess whether the use of the digital picture based Patient Benefit Assessment Scale improves the level of shared decision making. The I-Share questionnaire (appendix 3) is asked after the outpatient consult. • To assess whether the use of the digital picture baseds Patient Benefit Assessment Scale improves the quality of life of patients, measured with the SF-36 (appendix 4) at baseline and after three and six months after the first outpatient consult. level of shared decision making during the consultation experienced by patients. • To study the cost effectiveness of the digital picture based Patient Benefit Assessment Scale, measured with the EQ-5D-5L (appendix 5) at baseline and after three and six months after the first outpatient consult. • To examine whether the chosen treatment options of the intervention group differ from those of the control group. Based on the (electronic patient record the chosen treatment options can be analysed. The final comparison between treatments of the intervention group and the treatments of the control group is made after six months. ).

—

Countries

Netherlands

Contacts

Public ContactR.A.L. van Erp

Medisch Spectrum Twente (MST)

r.vanerp@mst.nl053-487-2040

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)